2024
Inflammatory bowel disease training assessment of gastroenterology fellows in Saudi Arabia.
AlDhneem H, AlMutairdi A, Attamimi M, Mosli M, AlAmeel T, Al-Bawardy B. Inflammatory bowel disease training assessment of gastroenterology fellows in Saudi Arabia. Saudi Journal Of Gastroenterology 2024, 30: 260-265. PMID: 38841910, PMCID: PMC11379256, DOI: 10.4103/sjg.sjg_19_24.Peer-Reviewed Original ResearchInflammatory bowel diseaseGI fellowsElderly/frail patientsAssociated with higher confidenceExternal rotationInflammatory bowel disease knowledgePreventive health servicesMulticenter survey studyManagement of inflammatory bowel diseaseInflammatory bowel disease managementGastroenterology fellowsHealth servicesSaudi ArabiaFellows' confidenceDidactic sessionsMethods of trainingExtraintestinal manifestationsCounseling patientsIBD patientsBowel diseaseIBD managementPatientsPreference learning methodLow confidenceConfidenceLonger Colonoscopy Withdrawal Time Is Associated With the Detection of Visible Dysplasia in Patients With Inflammatory Bowel Disease
McMillan C, Li D, Mohamed G, Alsadoun D, Almohsen L, Gaidos J, Proctor D, Al-Bawardy B. Longer Colonoscopy Withdrawal Time Is Associated With the Detection of Visible Dysplasia in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 2024, 6: otae020. PMID: 38585555, PMCID: PMC10998460, DOI: 10.1093/crocol/otae020.Peer-Reviewed Original ResearchColonoscopy withdrawal timeHigh-definition white light colonoscopyInflammatory bowel diseaseWhite light colonoscopyVisible dysplasiaBowel diseasePersonal historyWithdrawal timeAssociated with detectionEndoscopic healingAdenoma detectionDysplasia detectionDysplasia groupRetrospective studyAdult patientsInvisible dysplasiaColonoscopyPrimary outcomeDysplasiaMultivariate analysisPatientsIncreasing ageGeneral populationMinutesDiseaseEpstein-Barr virus seroprevalence among inflammatory bowel disease patients in Saudi Arabia
Al-Bawardy B, Alfadley A, Almousallam M, AlShathri S, Aboueissa M, Alsulaiman A, Attamimi M, AlMutairdi A. Epstein-Barr virus seroprevalence among inflammatory bowel disease patients in Saudi Arabia. Saudi Journal Of Gastroenterology 2024, 30: 168-172. PMID: 38358251, PMCID: PMC11198918, DOI: 10.4103/sjg.sjg_380_23.Peer-Reviewed Original ResearchSeroprevalence of EBVEpstein-Barr virusInflammatory bowel diseaseYears of ageEBV seroprevalenceEpstein-Barr virus statusCohort of IBD patientsDiagnosis of inflammatory bowel diseaseInflammatory bowel disease patientsRetrospective chart reviewFollow-up timeRate of seroconversionNon-exposureEBV seroconversionThiopurine therapyEBV-seropositiveNegative patientsTertiary centerIBD patientsPrimary outcomeSecondary outcomesBowel diseasePatientsVirus seroprevalenceDisease patientsUstekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease.
Petrov J, Fine S, Alzahrani R, Mohamed G, Al-Bawardy B. Ustekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease. Journal Of Clinical Gastroenterology 2024 PMID: 38300529, DOI: 10.1097/mcg.0000000000001978.Peer-Reviewed Original ResearchArea under the curveInflammatory bowel diseaseEndoscopic healingTrough levelsBowel diseaseAssociated with favorable outcomesUstekinumab trough levelsHighest area under the curveCohort of patientsTherapeutic drug monitoringClinical remissionCombination therapyMedian ageCRP normalizationRetrospective studyDrug levelsFavorable outcomeUstekinumabDrug monitoringPrimary outcomeSecondary outcomesCRPPatientsOutcomesHealing
2023
Saudi consensus guidance for the management of inflammatory bowel disease during pregnancy.
Azzam N, Almutairdi A, Almudaiheem H, AlAmeel T, Bakkari S, Alharbi O, Alenzi K, AlMolaiki M, Al-Omari B, Albarakati R, Al-Jedai A, Saadah O, Almadi M, Al-Bawardy B, Mosli M. Saudi consensus guidance for the management of inflammatory bowel disease during pregnancy. Saudi Journal Of Gastroenterology 2023, 30 PMID: 38099556, PMCID: PMC11379253, DOI: 10.4103/sjg.sjg_318_23.Peer-Reviewed Original ResearchInflammatory bowel diseaseManagement of IBDPregnant womenBowel diseaseClear evidence-based recommendationsSubset of patientsClinical care pathwayExpert opinion recommendationsOptimal patient managementEvidence-based recommendationsMultidisciplinary working groupCare pathwayClinical pharmacologyPatient managementPatient basisConsensus guidanceMultidisciplinary teamSaudi MinistryWomenPatientsDiseaseConcise guidelinesWorking GroupLiterature reviewManagementOutcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays
Al-Bawardy B, Jenkins S, Snyder M, Frinack J, Ladwig P, Loftus E, Willrich M. Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays. Clinical Biochemistry 2023, 119: 110618. PMID: 37507083, DOI: 10.1016/j.clinbiochem.2023.110618.Peer-Reviewed Original ResearchConceptsInflammatory bowel disease patientsBowel disease patientsEndoscopic healingClinical remissionDisease patientsMcg/Normal serum C-reactive proteinDrug monitoringSerum C-reactive proteinLC-MS/MSInfliximab drug levelsFavorable clinical outcomeC-reactive proteinTherapeutic drug monitoringIBD patientsNormal CRPClinical outcomesDrug levelsPatientsECLIARemissionDifferent assaysOutcomesMcgAssaysOutcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease
Sayed A, Assis D, Silveira M, Deng Y, Ciarleglio M, Gaidos J, Proctor D, Al-Bawardy B. Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease. European Journal Of Gastroenterology & Hepatology 2023, 35: 270-274. PMID: 36708297, DOI: 10.1097/meg.0000000000002510.Peer-Reviewed Original ResearchConceptsPrimary sclerosing cholangitisInflammatory bowel diseasePSC-IBDEndoscopic healingTherapy groupAdvanced therapiesClinical remissionBowel diseaseAcute ascending cholangitisRate of cholangitisSmall bowel involvementThird of patientsAscending cholangitisSclerosing cholangitisAdult patientsBowel involvementSecondary outcomesMedian agePrimary outcomeRetrospective studyHigh riskCholangitisPatientsTherapyLarger studyComparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study
Holmer A, Luo J, Russ K, Park S, Yang J, Ertem F, Dueker J, Nguyen V, Hong S, Zenger C, Axelrad J, Sofia A, Petrov J, Al-Bawardy B, Fudman D, Llano E, Dailey J, Jangi S, Khakoo N, Damas O, Barnes E, Scott F, Ungaro R, Singh S, Helping-IBD R. Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study. Clinical Gastroenterology And Hepatology 2023, 21: 1598-1606.e5. PMID: 36642291, DOI: 10.1016/j.cgh.2023.01.002.Peer-Reviewed Original ResearchConceptsNon-TNF biologicsInflammatory bowel diseaseProgression-free survivalRecurrence-free survivalTNFα antagonistsActive cancerPrior cancerCohort studyBiologic agentsBowel diseaseRecent cancerMulticenter retrospective cohort studyMulti-center cohort studyIBD disease severityRetrospective cohort studyChoice of biologicsTumor necrosis factorCohort BPrimary outcomeComparable safetyΑ antagonistsComparative safetyCancer recurrenceNecrosis factorPatients
2022
Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease
Mosli M, Almudaiheem H, AlAmeel T, Bakkari S, Alharbi O, Alenzi K, Khardaly A, AlMolaiki M, Al-Omari B, Albarakati R, Al-Jedai A, Saadah O, Almadi M, Al-Bawardy B. Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease. Saudi Journal Of Gastroenterology 2022, 29: s1-s35. PMID: 36412460, PMCID: PMC10540981, DOI: 10.4103/sjg.sjg_277_22.Peer-Reviewed Original ResearchInflammatory bowel diseaseBowel diseaseManagement of IBDExpert opinion-based recommendationsManagement of adultsOpinion-based recommendationsLevel of evidenceEvidence-based interventionsIBD diagnosisUlcerative colitisCrohn's diseaseConsensus guidelinesConsensus guidanceOptimal managementClinical pharmacyDiseaseSaudi MinistryAdultsDiagnosisConcise guidelinesGuidelinesLiterature reviewTime of writingColitisPatientsOpen-Capsule Budesonide for the Treatment of Isolated Immune Checkpoint Inhibitor-Induced Enteritis
Hussain N, Robert M, Al-Bawardy B. Open-Capsule Budesonide for the Treatment of Isolated Immune Checkpoint Inhibitor-Induced Enteritis. ACG Case Reports Journal 2022, 9: e00882. PMID: 36237281, PMCID: PMC9553371, DOI: 10.14309/crj.0000000000000882.Peer-Reviewed Original Research
2021
Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience
Ramos G, Al-Bawardy B, Neto M, Bledsoe A, Quinn K, Heron V, Willrich M, Johnson A, Chedid V, Coelho-Prabhu N, Kisiel J, Papadakis K, Pardi D, Kane S, Tremaine W, Raffals L, Bruining D, Faubion W, Harmsen W, Loftus E. Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience. Crohn's & Colitis 360 2021, 3: otab019. PMID: 36776673, PMCID: PMC9802288, DOI: 10.1093/crocol/otab019.Peer-Reviewed Original ResearchRadiologic responseClinical responseCertolizumab pegolMucosal healingCrohn's diseaseRadiologic healingCD patientsTrough levelsPositive antibody levelsSingle-center experienceCD outcomesAntibody levelsClinical managementOdds ratioCTL levelsHigher oddsRetrospective evaluationPatientsBiochemical responsesClinical practiceQuartile analysisAntibodiesCharacteristic curveOutcomesDisease
2020
The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study
Ramos GP, Dimopoulos C, McDonald NM, Janssens LP, Hung KW, Proctor D, Ruggiero E, Kane S, Bruining DH, Faubion WA, Raffals LE, Loftus EV, Al-Bawardy B. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. Inflammatory Bowel Diseases 2020, 27: 1270-1276. PMID: 33165569, DOI: 10.1093/ibd/izaa293.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseExtraintestinal manifestationsPeripheral arthritisBowel diseaseDose of vedolizumabPrevious biologic useMulticenter retrospective studyCurrent medical therapyTerms of ageConcurrent immunosuppressantsCorticosteroid therapyVDZ treatmentIBD subtypesBiologic useSecondary outcomesMedical therapyPrimary outcomeClinical outcomesMulticenter studyRetrospective studyVedolizumabPatientsCommon typeDiscontinuationArthritis
2019
Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease
Park S, Al-Bawardy B, Aniwan S, Kane S, Coelho-Prabhu N, Papadakis K, Kisiel J, Bruining D, Faubion W, Raffals L, Pardi D, Tremaine W, Stephens M, Tung J, Khanna S, Willrich M, Loftus E. Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 2019, 1: otz047. DOI: 10.1093/crocol/otz047.Peer-Reviewed Original ResearchAdalimumab trough levelsRadiologic responseDisease activityTrough levelsReferral center-based cohortInflammatory bowel disease patientsRadiologic disease activityBowel disease patientsInflammatory bowel diseaseC-reactive proteinDifferent therapeutic outcomesHigher cutoff levelsBowel diseaseDisease patientsCutoff levelTherapeutic outcomesCutoff valuePatientsCohortIBDLevelsDiseaseResponsePatient-oriented education and visual-aid intervention are inadequate to identify patients with potential capsule retention: a prospective randomized study
Al-Bawardy B, Kamboj AK, Desai S, Gorospe E, Bruining DH, Gostout CJ, Hansel SL, Larson MV, Murray JA, Nehra V, Leggett CL, Szarka LA, Watson RE, Rajan E. Patient-oriented education and visual-aid intervention are inadequate to identify patients with potential capsule retention: a prospective randomized study. Scandinavian Journal Of Gastroenterology 2019, 54: 662-665. PMID: 31034255, DOI: 10.1080/00365521.2019.1608465.Peer-Reviewed Original ResearchConceptsPatient-oriented educationVideo capsule endoscopyCapsule passageWB groupCapsule retentionProcedure-related risksSignificant differencesLack of visualizationBACKGROUND/Information bookletPatientsVerbal educationCapsule endoscopyStudy teamWrist bandInterventionGroupStatusPOE groupEndoscopyPoor indicatorAid interventionsDifferences
2018
Findings of CT-Derived Bone Strength Assessment in Inflammatory Bowel Disease Patients Undergoing CT Enterography in Clinical Practice
Maldonado FJ, Al Bawardy BF, Nehra AK, Lee YS, Bruining DH, Adkins MC, Keaveny TM, Johnson MP, Fidler JL, McCollough CH, Fletcher JG. Findings of CT-Derived Bone Strength Assessment in Inflammatory Bowel Disease Patients Undergoing CT Enterography in Clinical Practice. Inflammatory Bowel Diseases 2018, 25: 1072-1079. PMID: 30476314, DOI: 10.1093/ibd/izy341.Peer-Reviewed Original ResearchConceptsBiomechanical CT analysisBone mineral densityHigh fracture riskHigh-risk groupFracture riskCT enterographyIBD patientsFemoral neck bone mineral densityInflammatory bowel disease patientsNeck bone mineral densityWorld Health Organization classificationConsecutive IBD patientsFracture risk classificationBowel disease patientsFindings of CTMetabolic bone diseaseRetrospective reviewClinical featuresExact prevalenceDisease patientsOrganization classificationMineral densityBone diseasePatientsClinical practice
2017
Cross-sectional imaging in refractory celiac disease
Al-Bawardy B, Barlow JM, Vasconcelos RN, Kim ST, Bruining DH, Hansel SL, Sheedy SP, Murray JA, Rubio-Tapia A, Rajan E, Fidler JL, Fletcher JG. Cross-sectional imaging in refractory celiac disease. Abdominal Radiology 2017, 42: 389-395. PMID: 28084545, DOI: 10.1007/s00261-016-1032-0.Peer-Reviewed Original ResearchConceptsType II refractory celiac diseaseRefractory celiac diseaseCross-sectional imagingCeliac diseaseUlcerative jejunitisSB dilationSmall bowelResultsOne hundred eighteen patientsPattern abnormalitiesT-cell receptor rearrangementsUnique imaging findingsCell receptor rearrangementNon-significant trendType IDuodenal edemaJejunal foldsRefractory symptomsEighteen patientsMesenteric lymphadenopathyImaging findingsRetrospective studyRCD patientsType IIBlinded reviewPatientsCeliac disease: a clinical review
Al-Bawardy B, Codipilly DC, Rubio-Tapia A, Bruining DH, Hansel SL, Murray JA. Celiac disease: a clinical review. Abdominal Radiology 2017, 42: 351-360. PMID: 28078381, DOI: 10.1007/s00261-016-1034-y.BooksConceptsCeliac diseaseLifelong gluten-free dietRefractory celiac diseaseCornerstone of therapySmall bowel adenocarcinomaGluten-free dietMajority of patientsMinority of patientsT-cell lymphomaBowel adenocarcinomaGluten exposureDuodenal biopsiesInflammatory enteropathyAtypical manifestationsClinical reviewSerum serologyHigh prevalenceHigh indexSusceptible individualsUS populationPatientsEnteropathyComplicationsAdenocarcinomaBiopsy
2016
Outcomes of double-balloon enteroscopy-assisted direct percutaneous endoscopic jejunostomy tube placement
Al-Bawardy B, Gorospe EC, Alexander JA, Bruining DH, Coelho-Prabhu N, Rajan E, Wong Kee Song LM. Outcomes of double-balloon enteroscopy-assisted direct percutaneous endoscopic jejunostomy tube placement. Endoscopy 2016, 48: 552-556. PMID: 26964079, DOI: 10.1055/s-0042-101853.Peer-Reviewed Original ResearchConceptsJejunostomy tube placementAdverse eventsTube placementPost-procedural adverse eventsStudy aimDPEJ tube placementSerious adverse eventsSignificant adverse eventsMean procedure durationDouble-balloon enteroscopyTechnical success ratePatient demographicsCommon indicationSurgical repairGastric interpositionTechnical successMedical recordsProcedure durationLarge cohortDPEJSurgical adhesionsGut anatomyPatientsConventional endoscopyLarge series
2015
Transjugular intrahepatic portosystemic stent shunt for medically refractory hepatic hydrothorax: A systematic review and cumulative meta-analysis
Ditah IC, Al Bawardy BF, Saberi B, Ditah C, Kamath PS. Transjugular intrahepatic portosystemic stent shunt for medically refractory hepatic hydrothorax: A systematic review and cumulative meta-analysis. World Journal Of Hepatology 2015, 7: 1797-1806. PMID: 26167253, PMCID: PMC4491909, DOI: 10.4254/wjh.v7.i13.1797.Peer-Reviewed Original ResearchTransjugular intrahepatic portosystemic stent shuntRefractory hepatic hydrothoraxHepatic hydrothoraxSystematic reviewClass C diseaseRandom-effects modelComprehensive literature searchChild-TurcottMost patientsPoor prognosisMean ageMean durationEligible studiesC diseaseMean changePatientsLiterature searchHydrothoraxShuntI testsEMBASEPrognosisReviewEncephalopathyMmHg
2014
Comparative Effectiveness of Telaprevir-Based Triple Therapy in Patients With Chronic Hepatitis C
Al-Bawardy B, Kim WR, Poterucha JJ, Gross JB, Charlton MR, Larson JJ, Colby CL, Canterbury K, Warner J, Therneau TM. Comparative Effectiveness of Telaprevir-Based Triple Therapy in Patients With Chronic Hepatitis C. Mayo Clinic Proceedings 2014, 89: 595-601. PMID: 24661475, PMCID: PMC4160303, DOI: 10.1016/j.mayocp.2014.01.024.Peer-Reviewed Original ResearchConceptsRapid virologic responseChronic hepatitis CVirologic responseEarly virologic responseTriple therapyDual therapyHepatitis CP-IFNSustained virologic responseTreatment response categoriesTreatment-naive patientsPhase 3 trialRBV dose reductionPrior nonresponsePrior relapseCirrhosis statusProspective databaseViral hepatitisHemoglobin levelsAntiviral therapyWeek 4Dose reductionMean decreaseEligibility criteriaPatients